questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Hémoprotéines
Cytochromes
Cytochrome P-450 enzyme system
Famille-2 de cytochromes P450
Limonène hydroxylases
Limonène hydroxylases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Déficience enzymatique
Tests génétiques
Tests biochimiques
Activité enzymatique
Symptômes
Dysfonction enzymatique
Tests génétiques
Mutations
Symptômes
5
Troubles métaboliques
Réactions allergiques
Éruptions cutanées
Hypersensibilité
Troubles neurologiques
Symptômes
Prévention
5
Alimentation équilibrée
Nutriments
Tests génétiques
Surveillance précoce
Environnement de travail
Exposition
Traitements
5
Traitements symptomatiques
Modifications diététiques
Thérapie génique
Recherche
Thérapies alternatives
Gestion des symptômes
Complications
5
Complications métaboliques
Réactions allergiques
Risques à long terme
Maladies chroniques
Complications neurologiques
Cas rares
Facteurs de risque
5
Antécédents familiaux
Expositions environnementales
Facteurs environnementaux
Produits chimiques
Mode de vie
Complications
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Limonène hydroxylases : Questions médicales les plus fréquentes",
"headline": "Limonène hydroxylases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Limonène hydroxylases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-17",
"dateModified": "2025-04-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Limonène hydroxylases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Famille-2 de cytochromes P450",
"url": "https://questionsmedicales.fr/mesh/D000072467",
"about": {
"@type": "MedicalCondition",
"name": "Famille-2 de cytochromes P450",
"code": {
"@type": "MedicalCode",
"code": "D000072467",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.491"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9",
"url": "https://questionsmedicales.fr/mesh/D065729",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP2C9",
"code": {
"@type": "MedicalCode",
"code": "D065729",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.491.500.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 CYP2C19",
"alternateName": "Cytochrome P-450 CYP2C19",
"url": "https://questionsmedicales.fr/mesh/D065731",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP2C19",
"code": {
"@type": "MedicalCode",
"code": "D065731",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.491.500.700"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Limonène hydroxylases",
"alternateName": "Limonene Hydroxylases",
"code": {
"@type": "MedicalCode",
"code": "D065730",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sasa Liu",
"url": "https://questionsmedicales.fr/author/Sasa%20Liu",
"affiliation": {
"@type": "Organization",
"name": "College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Yuyao Ren",
"url": "https://questionsmedicales.fr/author/Yuyao%20Ren",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian, 116023, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Guojie Jin",
"url": "https://questionsmedicales.fr/author/Guojie%20Jin",
"affiliation": {
"@type": "Organization",
"name": "College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Xiaobing Yang",
"url": "https://questionsmedicales.fr/author/Xiaobing%20Yang",
"affiliation": {
"@type": "Organization",
"name": "College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China. yangxb@nwafu.edu.cn."
}
},
{
"@type": "Person",
"name": "Elham Zarenezhad",
"url": "https://questionsmedicales.fr/author/Elham%20Zarenezhad",
"affiliation": {
"@type": "Organization",
"name": "Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.",
"datePublished": "2022-07-19",
"url": "https://questionsmedicales.fr/article/35878575",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.nicl.2022.103109"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37473734",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000532022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development - (III) A Randomized Trial with Interferon Beta-1a Products.",
"datePublished": "2022-12-02",
"url": "https://questionsmedicales.fr/article/36324229",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cpt.2784"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.",
"datePublished": "2023-06-07",
"url": "https://questionsmedicales.fr/article/37273189",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/17425247.2023.2221432"
}
},
{
"@type": "ScholarlyArticle",
"name": "Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.",
"datePublished": "2022-07-14",
"url": "https://questionsmedicales.fr/article/35853357",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jneuroim.2022.577932"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hémoprotéines",
"item": "https://questionsmedicales.fr/mesh/D006420"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cytochromes",
"item": "https://questionsmedicales.fr/mesh/D003580"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytochrome P-450 enzyme system",
"item": "https://questionsmedicales.fr/mesh/D003577"
},
{
"@type": "ListItem",
"position": 7,
"name": "Famille-2 de cytochromes P450",
"item": "https://questionsmedicales.fr/mesh/D000072467"
},
{
"@type": "ListItem",
"position": 8,
"name": "Limonène hydroxylases",
"item": "https://questionsmedicales.fr/mesh/D065730"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Limonène hydroxylases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Limonène hydroxylases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Limonène hydroxylases",
"description": "Comment diagnostiquer une déficience en limonène hydroxylases ?\nQuels tests sont utilisés pour évaluer l'activité des limonène hydroxylases ?\nLes symptômes peuvent-ils indiquer un problème avec les limonène hydroxylases ?\nY a-t-il des biomarqueurs associés aux limonène hydroxylases ?\nComment les tests génétiques aident-ils au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Interferon+beta-1a#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Limonène hydroxylases",
"description": "Quels symptômes sont liés à une déficience en limonène hydroxylases ?\nLes symptômes varient-ils selon les individus ?\nPeut-on observer des symptômes cutanés ?\nLes symptômes respiratoires sont-ils fréquents ?\nY a-t-il des symptômes neurologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Interferon+beta-1a#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Limonène hydroxylases",
"description": "Peut-on prévenir les troubles liés aux limonène hydroxylases ?\nY a-t-il des mesures diététiques préventives ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nL'éducation sur les allergies est-elle importante ?\nLes environnements de travail peuvent-ils influencer la santé ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Interferon+beta-1a#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Limonène hydroxylases",
"description": "Quels traitements sont disponibles pour les troubles liés aux limonène hydroxylases ?\nLa thérapie génique est-elle une option ?\nDes médicaments spécifiques existent-ils ?\nComment la nutrition peut-elle aider ?\nLes traitements alternatifs sont-ils efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Interferon+beta-1a#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Limonène hydroxylases",
"description": "Quelles complications peuvent survenir avec une déficience en limonène hydroxylases ?\nLes complications sont-elles réversibles ?\nY a-t-il des risques à long terme ?\nLes complications affectent-elles la qualité de vie ?\nDes complications neurologiques sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Interferon+beta-1a#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Limonène hydroxylases",
"description": "Quels sont les facteurs de risque pour les troubles enzymatiques ?\nL'âge influence-t-il le risque de déficience ?\nLes allergies augmentent-elles le risque ?\nY a-t-il des facteurs environnementaux à considérer ?\nLe mode de vie joue-t-il un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Interferon+beta-1a#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en limonène hydroxylases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses génétiques peuvent être réalisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des limonène hydroxylases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant l'activité enzymatique dans des échantillons biologiques."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils indiquer un problème avec les limonène hydroxylases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes métaboliques peuvent suggérer une dysfonction enzymatique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés aux limonène hydroxylases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des métabolites spécifiques peuvent servir de biomarqueurs pour l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Comment les tests génétiques aident-ils au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils identifient des mutations dans les gènes codant pour les limonène hydroxylases."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une déficience en limonène hydroxylases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles métaboliques, des réactions allergiques ou des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'expression des symptômes peut varier en fonction de la génétique et de l'environnement."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées peuvent survenir en raison d'une hypersensibilité."
}
},
{
"@type": "Question",
"name": "Les symptômes respiratoires sont-ils fréquents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme l'asthme peuvent être exacerbés par des métabolites du limonène."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques peuvent survenir, mais ils sont moins fréquents."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux limonène hydroxylases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais éviter les allergènes peut aider à réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures diététiques préventives ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en nutriments peut soutenir la santé enzymatique."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier les individus à risque et permettre une surveillance précoce."
}
},
{
"@type": "Question",
"name": "L'éducation sur les allergies est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre les allergies peut aider à éviter les déclencheurs et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les environnements de travail peuvent-ils influencer la santé ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des environnements de travail exposant à des terpènes peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés aux limonène hydroxylases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements symptomatiques et des modifications diététiques peuvent être recommandés."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible pour ces troubles."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques existent-ils ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de médicaments spécifiques pour traiter ces déficiences."
}
},
{
"@type": "Question",
"name": "Comment la nutrition peut-elle aider ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut soutenir la fonction enzymatique."
}
},
{
"@type": "Question",
"name": "Les traitements alternatifs sont-ils efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives peuvent aider à gérer les symptômes, mais peu de preuves."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en limonène hydroxylases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications métaboliques et des réactions allergiques sévères peuvent se produire."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de maladies chroniques peuvent augmenter en raison de l'exposition continue."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent significativement impacter la qualité de vie des individus concernés."
}
},
{
"@type": "Question",
"name": "Des complications neurologiques sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, bien que rares, des complications neurologiques peuvent survenir dans certains cas."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles enzymatiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et des expositions environnementales peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de déficience ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences peuvent se manifester plus tard dans la vie."
}
},
{
"@type": "Question",
"name": "Les allergies augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes allergiques peuvent être plus susceptibles de développer des troubles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à considérer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques et à des terpènes peut être un facteur de risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque de complications liées aux enzymes."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 12/04/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian, 116023, People's Republic of China.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China. yangxb@nwafu.edu.cn.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran. m.osanloo@fums.ac.ir.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Energy Conversion and Storage, Faculty of Chemistry, Gdańsk University of Technology, G. Narutowicza 11/12, PL-80-233 Gdańsk, Poland.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Institute of Fluid-Flow Machinery, Polish Academy of Sciences, Fiszera 14 st., PL-80-231 Gdańsk, Poland.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
School of Food Engineering, Department of Food Science, University of Campinas, Campinas, Brazil.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, USA. vhgrassian@ucsd.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, University of California, Irvine, California 92697, USA. dtobias@uci.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, University of California, Irvine, California 92697, USA. dtobias@uci.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, USA. vhgrassian@ucsd.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA.
Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA.
Center for Synthetic Biology, Northwestern University, Evanston, IL, USA.
Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute Northwestern University, Chicago, IL, USA.
Simpson Querrey Institute Northwestern University, Chicago, IL, USA.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
DECHEMA-Forschungsinstitut, Industrial Biotechnology, Frankfurt am Main, Germany.
Faculty Biological Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
DECHEMA-Forschungsinstitut, Industrial Biotechnology, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
DECHEMA-Forschungsinstitut, Industrial Biotechnology, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
Faculty Biological Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
Myelin water imaging is a magnetic resonance imaging (MRI) technique that quantifies myelin damage and repair in multiple sclerosis (MS) via the myelin water fraction (MWF)....
In this substudy of a phase 3 therapeutic trial, OPERA II, MWF was assessed in relapsing MS participants assigned to interferon beta-1a (IFNb-1a) or ocrelizumab (OCR) during a two-year double-blind pe...
MWF in normal appearing white matter (NAWM), including both whole brain NAWM and 5 white matter structures, and chronic lesions, was assessed in 29 OCR and 26 IFNb-1a treated participants at weeks 0, ...
Linear mixed-effects models of data from baseline to week 96 showed a difference in the change in MWF over time favouring ocrelizumab in all NAWM regions. At week 192, lesion MWF was lower for partici...
Ocrelizumab appears to protect against demyelination in MS NAWM and chronic lesions and may allow for a more permissive micro environment for remyelination to occur in focal and diffusely damaged tiss...
Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously be...
Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as t...
A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Chan...
Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight int...
The US Food and Drug Administration (FDA) has taken steps to bring efficiency to the development of biosimilars, including establishing guidance for the use of pharmacokinetic and pharmacodynamic (PD)...
Self-administration of subcutaneous interferon beta-1a (sc IFN β-1a) can be achieved with the RebiSmart® electromechanical autoinjector. This study investigated adherence to, and duration of persisten...
This retrospective, observational study utilized data from RebiSmart® devices, recorded on the MSdialog database, between January 2014 and November 2019. Adherence and persistence were evaluated over ...
The population of RebiSmart® users (...
People living with MS were highly adherent to use of the RebiSmart® device, with higher persistence generally observed for older and/or male individuals....
A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif™) develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We hypothesized t...
A 62-year-old woman with a history of multiple sclerosis (MS) presented with recurrent episodes of confusion, dysarthria and gait difficulties. These episodes occurred about 3 days after administratio...
Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disorder. Elevated levels of pro-inflammatory mediators and some oxidative stress parameters can accelerate the demyelination proce...
Eighty RRMS patients were equally divided into 2 groups: the intervention group receiving IFNβ-1a plus 2 gm of metformin once daily and the control group receiving IFNβ-1a alone. Interleukin 17 (IL17)...
At baseline, there were no statistically significant differences between the two groups (p > 0.05). After 6 months, the change in the median (interquartile range) of the results for both the intervent...
Adding metformin to IFNβ-1a demonstrated a potential effect on an oxidative stress marker (MDA). However, there is no statistically significant effect on immunological, MRI and clinical outcomes. We r...
ClinicalTrials.gov number: NCT05298670, 28/3/2022....
Interferon (IFN)-β-1a (Avonex) and longer half-life, polyethylene glycol-conjugated IFN-β-1a (PEG-IFN-β-1a, Plegridy), may generate different molecular responses. We identified different short-term an...
With few approved multiple sclerosis therapies in the pediatric population, there is a need for further approved treatment options. Limited data exist for dimethyl fumarate (DMF) treatment in pediatri...
To compare the efficacy, safety, and tolerability of DMF vs intramuscular interferon β-1a (IFNβ-1a) in POMS....
The CONNECT study was an active-controlled, open-label, rater-blinded 96-week randomized clinical trial in patients with POMS aged 10 to less than 18 years treated between August 2014 and November 202...
Patients were randomized to DMF or IFNβ-1a....
The primary end point was the proportion of patients free of new or newly enlarging (N or NE) T2 hyperintense lesions at week 96 among trial completers. Secondary end points included number of N or NE...
Among 150 patients with POMS in the intention-to-treat (ITT) population (median [range] age, 15 [10-17] years; 101 [67.3%] female patients), 78 individuals received DMF and 72 individuals received IFN...
This study found that more pediatric patients with POMS treated with DMF were free of new or newly enlarging T2 lesions and that the adjusted ARR was lower among these patients compared with those tre...
ClinicalTrials.gov Identifier: NCT02283853....
Interferon beta therapies are well-established disease-modifying treatments for patients with relapsing multiple sclerosis (MS). Based on clinical evidence from two large cohort studies, both, the EMA...
The post-authorisation safety study PRIMA included adult women diagnosed with relapsing-remitting MS or clinically isolated syndrome, who were treated with peginterferon beta-1a or IM interferon beta-...
In total, 426 women were enrolled, reporting 542 pregnancies that resulted in 466 live births. A total of 162 women completed the questionnaire for 192 live births (53.1% male). Newborns had Apgar sco...
Study results confirmed former reports indicating that exposure to interferon beta therapies during pregnancy or lactation had no adverse effects on intrauterine growth and child development over the ...
NCT04655222, EUPAS38347....